- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03009019
Efficacy, Tolerability, and Safety of DFN-15
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Site 609
-
Mobile, Alabama, United States, 36608
- Site 640
-
-
Arizona
-
Tucson, Arizona, United States, 85745
- Site 622
-
-
Arkansas
-
Hot Springs, Arkansas, United States, 71901
- Site 616
-
-
California
-
Huntington Beach, California, United States, 92647
- Site 637
-
Oakland, California, United States, 94607
- Site 615
-
San Diego, California, United States, 92108
- Site 646
-
San Francisco, California, United States, 94102
- Site 619
-
San Marcos, California, United States, 92078
- Site 624
-
-
Colorado
-
Littleton, Colorado, United States, 80127
- Site 631
-
-
Florida
-
Miami, Florida, United States, 33176
- Site 603
-
Orange City, Florida, United States, 32763
- Site 641
-
Orlando, Florida, United States, 32801
- Site 629
-
West Palm Beach, Florida, United States, 33409
- Site 601
-
-
Georgia
-
Decatur, Georgia, United States, 30034
- Site 625
-
Sandy Springs, Georgia, United States, 30328
- Site 630
-
-
Idaho
-
Meridian, Idaho, United States, 83642
- Site 642
-
-
Illinois
-
Blue Island, Illinois, United States, 60406
- Site 604
-
-
Kentucky
-
Louisville, Kentucky, United States, 40213
- Site 602
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70115
- Site 644
-
New Orleans, Louisiana, United States, 70124
- Site 610
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48104
- Site 634
-
-
Minnesota
-
Edina, Minnesota, United States, 55435
- Site 623
-
-
Missouri
-
Saint Peters, Missouri, United States, 63303
- Site 638
-
-
Montana
-
Missoula, Montana, United States, 59808
- Site 606
-
-
Nebraska
-
Omaha, Nebraska, United States, 68134
- Site 613
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Site 647
-
Nashua, New Hampshire, United States, 03060
- Site 618
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Site 636
-
-
New York
-
Brooklyn, New York, United States, 11229
- Site 645
-
Rochester, New York, United States, 14609
- Site 608
-
-
North Carolina
-
High Point, North Carolina, United States, 27262
- Site 620
-
Mooresville, North Carolina, United States, 28117
- Site 643
-
-
North Dakota
-
Fargo, North Dakota, United States, 58103
- Site 626
-
-
Ohio
-
Cleveland, Ohio, United States, 44122
- Site 628
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02886
- Site 614
-
-
South Carolina
-
Mount Pleasant, South Carolina, United States, 29464
- Site 639
-
-
South Dakota
-
Dakota Dunes, South Dakota, United States, 57049
- Site 612
-
-
Texas
-
Austin, Texas, United States, 78745
- Site 627
-
Dallas, Texas, United States, 75231
- Site 611
-
San Antonio, Texas, United States, 78240
- Site 632
-
-
Utah
-
Taylorsville, Utah, United States, 84123
- Site 621
-
-
Virginia
-
Richmond, Virginia, United States, 23294
- Site 635
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A history of episodic migraine, who experience 2 to 8 migraine attacks per month for at least the past 12 months, with no more than 14 headache days per month, and with 48 hours of headache-free time between migraine attacks.
- Patients who have migraine with or without aura with onset before age 50 years
- Report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity scale without treatment.
Subjects who are willing and able to:
- Evaluate and record pain, migraine symptoms, and study drug effectiveness information in real-time using a subject eDiary for the duration of the study;
- Record each instance of the use of study drug and rescue medication in real-time using a subject eDiary for the duration of the study;
- Comply with all other study procedures and scheduling requirements.
Exclusion Criteria:
- Minors, even if they are in the specified study age range
Medication overuse:
- Opioids greater than or equal to 10 days during the 90 days prior to screening
- Combination medications (e.g., Fiorinal®) greater than or equal to 10 days during the 90 days prior to screening (applies only if includes opioid and/or barbiturate)
- Nonsteroidal Anti-inflammatory Drugs or other simple medications greater than 14 days a month during the 90 days prior to screening
- Triptans or ergots greater than or equal to 10 days a month during the 90 days prior to screening
- Treated with onabotulinumtoxin A (Botox®) for migraine within 4 months prior to screening. (If treated for cosmetic reasons, subjects may be included).
- Current treatment with antipsychotics or use of antipsychotics within 30 days prior to randomization.
- Patients who have received treatment with an investigational drug or device within 30 days of randomization, or participated in a central nervous system clinical trial within 2 months prior to randomization
- Patients with positive screening test for human immunodeficiency virus [HIV], positive hepatitis B surface antigen (HBsAg), or positive hepatitis C virus [HCV] antibody
- Subjects who are employees or immediate relatives of the employees of the Sponsor, any of its affiliates or partners, or of the clinical research study site.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DFN-15 Active
|
Other Names:
|
Placebo Comparator: DFN-15 Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (First Treated Double-blind Treatment Period)
Time Frame: 2 hours postdose
|
The primary efficacy end point (for first treated DB1 attack only) were the percentage of subjects who were pain-free 2 hours postdose compared between DFN-15 and placebo (defined as a reduction from predose moderate [Grade 2] or severe [Grade 3] pain to none [Grade 0]
|
2 hours postdose
|
Percentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose
Time Frame: 2 hours postdose
|
Percentage of subjects who are free from their Most Bothersome Symptom (MBS) among nausea, photophobia, and phonophobia (first double-blind treatment period)
|
2 hours postdose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Number of Subjects With TEAEs After Study Drug Compared Between DFN-15 and Placebo
Time Frame: Per protocol, the maximum dosing timeframe for DB2 was 10 weeks; therefore, the maximum AE collection window was 11 weeks total.
|
For DB1: TEAE that started or worsening of a pre-existing condition on or after the first dose of study drug (DFN-15 or placebo) in to taking DB2 study drug, whichever occurs first. For DB2: TEAE that started or worsened on or after the first dose of study drug in DB2 up to 5 days after the date of the last dose of study drug in DB2. |
Per protocol, the maximum dosing timeframe for DB2 was 10 weeks; therefore, the maximum AE collection window was 11 weeks total.
|
Freedom From Nausea, Photophobia, and Phonophobia Postdose (DB1 and DB2)
Time Frame: 15 minutes to 24 hours postdose
|
The percentage of subjects who were free from nausea, photophobia, and phonophobia at 15, 30, and 45 minutes and 1, 1.5, 2, 4, and 24 hours postdose compared between DFN-15 and placebo
|
15 minutes to 24 hours postdose
|
Time to Headache Pain Relief Postdose (DB1 and DB2)
Time Frame: 2 hours postdose
|
The time to headache pain relief was defined as the time in minutes from when a subject took study drug until the time pain relief was indicated by the subject in the eDiary within 2 hours postdose.
|
2 hours postdose
|
Time to Headache Pain Freedom Postdose (DB1 and DB2)
Time Frame: 2 hours postdose
|
The time to headache pain freedom was defined as the time in minutes from when a subject took study drug until the time pain freedom was indicated by the subject in the eDiary within 2 hours postdose.
|
2 hours postdose
|
Headache Pain Relief Postdose (DB1 and DB2)
Time Frame: 15 minutes to 24 hours postdose
|
Headache pain relief was defined for DB1 as a reduction from moderate or severe pain before dosing to mild or none postdose, and for DB2 as moderate or severe pain before dosing reduced to mild or none postdose, or mild pain before dosing reduced to none postdose.
Data are reported by percentage reporting headache pain relief over time postdose.
|
15 minutes to 24 hours postdose
|
Headache Pain Freedom Postdose (DB1 and DB2)
Time Frame: 15 minutes to 24 hours postdose
|
The percentage of subjects who were pain-free at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose compared between DFN-15 and placebo
|
15 minutes to 24 hours postdose
|
Absence of Screening MBS at Time Points Postdose (DB1 and DB2)
Time Frame: 15 minutes to 24 hours postdose
|
The percentage of subjects with their Screening MBS (Most Bothersome Symptom) absent at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose compared between DFN-15 and placebo.
|
15 minutes to 24 hours postdose
|
Change in Functional Disability Score Postdose (DB1 and DB2)
Time Frame: 2 to 24 hours postdose
|
Change in functional disability score at 2, 4, and 24 hours postdose compared between DFN-15 and placebo. The values of the functional disability scale were: 0=no disability, able to function normally; 1=performance of daily activities mildly impaired, can still do everything but with difficulty; 2=performance of daily activities moderately impaired, unable to do some things; 3=performance of daily activities severely impaired, cannot do all or most things, bed rest may be necessary. A decrease in values indicates improvement from baseline. |
2 to 24 hours postdose
|
Headache Pain Freedom Among Subjects With Cutaneous Allodynia (DB1 and DB2)
Time Frame: 2 and 4 hours postdose
|
The percentage of subjects who were pain-free at 2 and 4 hours postdose compared between DFN-15 and placebo, among those reporting cutaneous allodynia predose
|
2 and 4 hours postdose
|
Headache Pain Freedom Among BMI Category (DB1 and DB2)
Time Frame: 2 and 4 hours postdose
|
The percentage of subjects who were pain-free at 2 and 4 hours postdose whose BMI was < 30 kg/m2 vs. subjects whose BMI was ≥ 30 kg/m2, and whose BMI was < 25 kg/m2 vs. subjects whose BMI was ≥ 25 kg/m2
|
2 and 4 hours postdose
|
Headache Pain Recurrence Postdose (DB1 and DB2)
Time Frame: 2 to 24 hours postdose
|
The percentage of subjects who had pain recurrence between 2 to 24 hours (i.e., pain-free at 2 hours postdose, with pain [mild, moderate, or severe] reported at 24 hours postdose) compared between DFN-15 and placebo
|
2 to 24 hours postdose
|
Sustained Headache Pain Relief Postdose (DB1 and DB2)
Time Frame: 2 to 24 hours postdose
|
The percentage of the population of subjects who reported headache pain relief between 2 and 24 hours postdose.
|
2 to 24 hours postdose
|
Sustained Headache Pain Freedom Postdose (DB1 and DB2)
Time Frame: 2 to 24 hours postdose
|
The percentage of subjects who had sustained pain freedom at 2 to 24 hours postdose compared between DFN-15 and placebo in each DB period.
Sustained pain freedom at 2 to 24 hours postdose is defined as pain-free at 2 hours postdose, with no use of rescue medication, and no recurrence of headache pain within 2 to 24 hours postdose
|
2 to 24 hours postdose
|
Use of Rescue Medication Postdose (DB1 and DB2)
Time Frame: 2 to 24 hours postdose
|
The percentage of subjects who used rescue medication after 2 hours (2 to 24 hours) postdose compared between DFN-15 and placebo in each DB period
|
2 to 24 hours postdose
|
Subject-Rated Treatment Satisfaction Postdose (DB1 and DB2)
Time Frame: 2 and 4 hours postdose
|
Subject-rated treatment overall satisfaction was based on a 7-point scale at 2 and 4 hours postdose during each DB treatment period. The difference between the subject-rated study drug treatment satisfaction score at 2 and 4 hours postdose and the baseline PPMQ-R (Patient Perception of Migraine Questionnaire) response for the same question were summarized by treatment group (global satisfaction item at baseline asked about the subject's usual migraine treatment). The possible values of the subject treatment satisfaction scale were: 1=very satisfied, 2=satisfied, 3=somewhat satisfied, 4=neither satisfied nor dissatisfied, 5=somewhat dissatisfied, 6=dissatisfied, 7=very dissatisfied. A decrease in values indicates improvement from baseline. |
2 and 4 hours postdose
|
Subject-Rated Treatment Satisfaction at 24 Hours Postdose - PPMQ-R (DB1 and DB2)
Time Frame: 24 hours postdose
|
Patient Perception of Migraine Questionnaire-Revised had 30 questions assessing subject's satisfaction with migraine medication, including 3 global items & 4 subscales (i.e., efficacy, function, ease of use, tolerability).
A 5-point scale (1-Not At All to 5-Extremely) was used for tolerability subscale questions; a 7-point scale (1-Very Satisfied to 7-Very Dissatisfied) was used for all other subscales and global items.
Total score was average of efficacy/function/ease of use subscale scores.
Each subscale & total scores were transformed to range from 0-100, with higher scores indicating better satisfaction or tolerability.
Total raw score/global items were not transformed.
The total raw score could range from 17 (min) to 119 (max), with lower scores indicating better satisfaction.
Change from baseline scores at 24-hour-postdose for each subscale score, global item score, total score, & total raw score were summarized by treatment group below.
|
24 hours postdose
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Headache
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Celecoxib
Other Study ID Numbers
- DFN-15-CD-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine Headache
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
-
Ariston Pharmaceuticals, Inc.UnknownMigraine | Migraine Disorders | Migraine Headache | Migraine Without Aura | Migraine With AuraFinland, Netherlands, United Kingdom
-
Danish Headache CenterCompletedHeadache, Migraine | AuraDenmark
-
Click Therapeutics, Inc.Active, not recruitingMigraine | Headache | Headache, Migraine | Episodic MigraineUnited States
-
Click Therapeutics, Inc.Active, not recruitingMigraine | Headache | Headache, Migraine | Episodic MigraineUnited States
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Behar, Caren, M.D.UnknownMigraine | Migraine Disorders | Migraine Headache | Acute MigraineUnited States
-
Nanfang Hospital, Southern Medical UniversityBrainClos Co., LTD.; Zhuhai Fudan Innovation InstituteNot yet recruitingCluster Headache | Migraine in Children | Tension Headache | Migraine in Adolescence | Primary HeadacheChina
-
Children's Hospital Medical Center, CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMigraine | Migraine Disorders | Headache | Headache Disorders | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
-
Danish Headache CenterCompletedMigraine Headache | Migraine Without AuraDenmark
Clinical Trials on DFN-15 Active
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
BioDelivery Sciences InternationalCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedTerminatedMedication Overuse HeadacheUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
LEO PharmaBayerCompletedPerioral DermatitisGermany
-
Merck Sharp & Dohme LLCCompletedPneumococcal DiseaseKorea, Republic of